Theravance and Merck Sign Cardiovascular Disease Collaboration
October 16, 2012 08:00 ET
|
Theravance, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) announced today that it has signed a collaboration agreement with Merck, known as MSD outside the United...
Theravance and Alfa Wassermann Enter Into Agreement to Develop and Commercialize Velusetrag for Gastroparesis
October 02, 2012 16:05 ET
|
Theravance, Inc.
SOUTH SAN FRANCISCO, Calif. and BOLOGNA, Italy, Oct. 2, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) and Alfa Wassermann S.p.A. announced today that they have entered into an exclusive...
GSK and Theravance Announce FDA Acceptance of FF/VI New Drug Application (NDA) Submission in the US for COPD
September 26, 2012 04:00 ET
|
Theravance, Inc.
LONDON and SOUTH SAN FRANCISCO, Calif., Sept. 26, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (Nasdaq:THRX) today announced that the New Drug Application (NDA) for the...
Theravance to Present at the Morgan Stanley Global Healthcare Conference
August 29, 2012 16:05 ET
|
Theravance, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at...
GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD
August 24, 2012 07:03 ET
|
Theravance, Inc.
LONDON and SOUTH SAN FRANCISCO, Calif., Aug. 24, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (Nasdaq:THRX) today announced the completion of the phase III programme of an...
Theravance Reports Second Quarter 2012 Financial Results
July 31, 2012 16:05 ET
|
Theravance, Inc.
SOUTH SAN FRANCISCO, Calif., July 31, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) reported today its financial results for the quarter ended June 30, 2012. Revenue for the second quarter...
Theravance to Report Second Quarter 2012 Financial Results on July 31, 2012
July 17, 2012 16:05 ET
|
Theravance, Inc.
SOUTH SAN FRANCISCO, Calif., July 17, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) announced today that it will release financial results for the period ended June 30, 2012 after market...
GSK and Theravance Announce Regulatory Submissions for FF/VI in the US and Europe
July 13, 2012 07:00 ET
|
Theravance, Inc.
LONDON and SOUTH SAN FRANCISCO, Calif., July 13, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (Nasdaq:THRX) today announced the submission of regulatory applications in the...
Theravance Announces Positive Topline Results From TD-1211 Phase 2b Study 0084 for the Treatment of Opioid-Induced Constipation
July 10, 2012 16:05 ET
|
Theravance, Inc.
SOUTH SAN FRANCISCO, Calif., July 10, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) today announced positive topline results from 0084, the key study in the Phase 2b program evaluating...
GSK and Theravance Announce Positive Results From Four Pivotal Phase III Studies for Once-Daily LAMA/LABA (UMEC/VI) in COPD
July 02, 2012 02:06 ET
|
Theravance, Inc.
LONDON and SOUTH SAN FRANCISCO, Calif., July 2, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE:GSK) and Theravance, Inc. (Nasdaq:THRX) today announced the results of four pivotal phase III...